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This study presents the case of a female patient with severe heterozygous familial 
hypercholesterolemia. Despite the combined maximum dose oral treatment with rosuvastatin 
and ezetimibe, we found markedly elevated lipid parameters. Therefore, we indicated monthly 
selective low density lipoprotein (LDL) apheresis treatment using the Direct Adsorption of 
Lipoproteins system. After more than 2 years the lipid levels of the patients were still above the 
therapeutic goals. Finally, we completed the treatment by the inhibitor evolocumab biweekly. 
Further LDL cholesterol (LDL-C) reduction was achieved resulting in lipid parameters on 
goals. However, administration of evolocumab without LDL apheresis could not reduce the 
LDL-C below 2.5 mmol/L. We concluded that both LDL apheresis and proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitor treatments were effective and well tolerated. None of 
them alone would be enough to achieve lipid goals in this patient. However, the combination of 
these potent treatments may normalize the lipid levels and prevent cardiovascular complications.
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INTRODUCTION
Familial hypercholesterolemia (FH) is perhaps the 
most common single-gene variant causing premature 
morbidity and mortality. Heterozygous FH affects 
about 1 in 200 people.[1] Genetic loci involved in FH 
phenotype include LDLR (low-density lipoprotein 
receptor), APOB (apolipoprotein B-100), and PCSK9 
(proprotein convertase subtilisin/kexin type 9).[2] 
The FH phenotype is based on family history, LDL 
cholesterol (LDL-C) levels, and presence of physical 
findings such as xanthomas, xanthelasma and corneal 
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arcus. This allows for risk assessment and diagnosis 
when genetic testing is not available. Criteria that are 
most commonly used in the diagnosis of FH is the 
Dutch Lipid Network criteria.[3] Genetic testing is critical 
for cascade screening and genetic counseling.[1]
Total cholesterol levels of 350-550 mg/dL (9-
14.2 mmol/L) are typical of heterozygous FH while 
total cholesterol levels of 650-1,000 mg/dL (16.8-
25.9 mmol/L) are typical of homozygous FH.[4] In 
heterozygous patients LDL-C levels are usually > 
190 mg/dL (> 4.9 mmol/L). In adults with homozygous 
FH, untreated LDL-C levels are generally, but not 
always, > 500 mg/dL (> 13 mmol/L). However, levels 
can be lower in children or in treated individuals. Thus, 
LDL-C levels are not sufficient to confirm a diagnosis.[5]
FH is associated with high risk of enhanced 
atherogenesis leading to the early development 
of coronary artery disease (CAD), carotid artery 
disease and peripheral artery disease. The European 
Atherosclerosis Society suggests LDL-C goals of less 
than 100 mg/dL (2.59 mmol/L) in all adults with FH, and 
less than 70 mg/dL (1.81 mmol/L) in adults with known 
CAD or diabetes mellitus.[3] Therefore, there is an 
ardent need for an aggressive therapeutic intervention 
based on high dose statin or statin and ezetimibe 
administration, selective LDL-apheresis or newly 
developed further therapeutic strategies including the 
inhibition of PCSK9.[6]
LDL apheresis techniques are artificial extracorporeal 
methods for LDL-C elimination. There are various 
methods, including cascade filtration or lipid filtration, 
immunoadsorption, heparin-induced LDL precipitation, 
dextran sulfate LDL adsorption, and the LDL 
hemoperfusion. All of these techniques are effective 
and well tolerated. The constant reduction of cholesterol 
is meant, above all, to prevent the progression or the 
development of atherosclerosis.[7]
Human monoclonal antibodies against PCSK9: 
alirocumab and evolocumab have recently been 
approved by the Food and Drug Administration. 
These agents target and inactivate PCSK9, a hepatic 
protease that attaches and internalizes LDL receptors 
into lysosomes hence promoting their destruction.[8] 
By preventing LDL receptor destruction, LDL-C levels 
can be lowered 50-60% above that achieved by statin 
therapy alone.[9] Although the data are deficient, 
PCSK9 inhibitors may reduce the frequency or even 
eliminate the need for LDL apheresis therapy. A recent 
study reported that switching from LDL apheresis to 
evolocumab maintained the LDL-lowering effect but 
did not decrease high-density lipoprotein cholesterol 
(HDL-C) levels in three patients with heterozygous 
FH and coronary artery disease.[10] Furthermore, 
findings from the ODYSSEY ESCAPE study suggest 
a role for alirocumab in the overall management of 
patients with heterozygous FH undergoing regular 
lipoprotein apheresis therapy, with the potential to 
avoid apheresis treatments or delay the requirement 
for such treatments.[11]
Here we demonstrate the efficacy of selective LDL 
apheresis, PCSK9 inhibitor evolocumab and the 
combination of the two treatment strategies in the case 
of a severe heterozygous FH patient.
CASE REPORT
The 48-year-old female patient (body weight: 
85 kg, height: 176 cm, body mass index: 27.4 kg/m2) 
with extremely high total cholesterol, LDL-C and 
lipoprotein(a) [Lp(a)] levels was treated by our Lipid 
ambulance. She had xanthelasmas on both eye lids 
[Figure 1], but neither xanthoma nor corneal arcus 
could be seen.
Carotid artery ultrasound proved significant stenosis 
on both sides. Electrocardiography, echocardiography 
and exercise electrocardiography did not show the 
signs of CAD. Using the Dutch Lipid Network Criteria 
the diagnosis of FH is “probable”. Sequencing of the 
LDL receptor gene we found a known pathogenic 
mutation in heterozygous form (c.1865 A>G, exon 
13). Since the hypercholesterolemia, we found is 
unexpectedly severe in heterozygous FH, further 
genetic tests are in process. Although mildly 
elevated triglyceride (3.1 mmol/L) and lower HDL-C 
(1.1 mmol/L) levels are not usual in FH, the fact that 
the patient was overweight may explain this.
Despite the maximum dose of combined treatment 
(rosuvastatin 40 mg/day, ezetimibe 10 mg/day, 
fenofibrate 267 mg/day), lipid levels were continuously 
high above the goals (total cholesterol 11.7 mmol/L, 
LDL-C 9.1 mmol/L). Therefore, we indicated the 
selective LDL apheresis treatment once a month 
(financially supported by the Hungarian National 
Health Insurance Company). We performed the 
Figure 1: Xanthelasma on both eye lids of the patient with 
heterozygous familial hypercholesterolemia
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treatments in the Extracorporeal Organ Replacement 
Center of University of Debrecen using the Direct 
Adsorption of Lipoproteins (DALI) system (Fresenius 
Medical Care). The DALI system can remove ApoB 
containing lipoproteins from the whole blood in one 
step without prior plasma separation. We used DALI 
750 columns, 1:20 proportioned ACD-A (citrate 
solution) for anticoagulation. Average treated volume 
was 8,058 mL/treatment. The total cholesterol, LDL-C 
[Figure 2] and Lp(a) levels markedly decreased.
During the first two treatments we observed mild 
and transient bradykinin reactions with hypotension, 
dyspnea, atypical chest pain and flushing. After three 
treatments apheresis was suspended for three months 
at the patient’s wish. Then, because of increasing lipid 
levels we continued apheresis treatment. Although 
between two treatments there was an increase in lipid 
levels, the time-average cholesterol (TAC) and LDL-
cholesterol (TAL) levels calculated with a formula 
by Kroon et al.[12] decreased significantly (TAC: 
6.44 mmol/L, TAL: 4.68 mmol/L). Monthly apheresis 
treatment decreased TAC by 45.7% and TAL by 
48.6%. The average reduction of Lp(a) level was 72%. 
Despite the efficacy of monthly apheresis treatments, 
lipid levels were still above the goals. Theoretically, we 
could increase the frequency of apheresis treatments 
and administer it biweekly, however, our insurance 
company would not support it because of its high costs. 
One of the two PCSK9 inhibitor monoclonal antibodies 
available in Hungary since 2015 is evolocumab. We 
decided to start this new agent added to the LDL 
apheresis treatment. Evolocumab was administrated 
biweekly, subcutaneously in a dose of 140 mg/day. 
After two months of combined apheresis plus PCSK9 
inhibitor treatments we detected further significant 
reductions in total cholesterol and LDL-C levels (62.1% 
and 66.1%, respectively), and finally, we achieved 
the lipid goals. Hoping that the PCSK9 inhibitor 
treatment would be effective without further apheresis 
treatments, we stopped the apheresis and continued 
the evolocumab therapy. Unfortunately, despite the 
impressive efficacy of the PCSK9 inhibition, after a 
further three months the patient was above the goals 
[Figures 2 and 3].
DISCUSSION
Adequate treatment of patients with FH is a challenge 
and an everyday problem for the therapists. 
Combination of high dose oral lipid lowering agents is 
in some severe cases not effective enough because of 
the extremely high initial lipid levels. Our demonstrated 
case is a good example for this situation. Selective 
LDL apheresis treatments are available and widely 
used since the 80s. Removal of the ApoB containing 
lipoprotein particles can reduce the total cholesterol 
and LDL-C levels by 50-75% acutely. The TAC shows 
inter-individual differences and is usually between 20% 
to 40%.[13] In our case the reduction was even higher.
Moreover, LDL apheresis can markedly reduce the 
Lp(a) levels even by 60-80%. Lp(a) is an independent 
risk factor for cardiovascular disease and is not lowered 
by oral lipid-lowering therapy apart from nicotinic 
acid.[14] In our case, LDL apheresis showed similar 
Figure 2: Total cholesterol/TAC and low-density lipoprotein cholesterol/TAL levels of the patient during the treatments. TAC = Cmin + 
0.73(Cmax - Cmin); TAL = LDLmin + 0.73(LDLmax - LDLmin). LDL-C: low density lipoprotein cholesterol; TAC: time average cholesterol; TAL: 
time average low-density lipoprotein cholesterol
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Lp(a) reduction. It must be noted that from the initiation 
of the apheresis treatments regular carotid ultrasound 
examinations did not show any progression and CAD 
was not diagnosed.
One hundred and forty mg biweekly administrated 
evolocumab can reduce the LDL-C level by 66%.[15] 
PCSK9 inhibition also results in significant (18-
20%) reductions in plasma Lp(a). Unique efficacy of 
evolocumab in LDL-C reduction could be observed 
in our case. However, LDL apheresis treatment is 
superior in Lp(a) reduction.
So, which treatment strategy should we choose in our 
severe heterozygous FH patients? Would selective 
LDL apheresis or PCSK9 inhibition be better? Decades 
of clinical experience, results of long-term follow-
up studies[16,17] and unique Lp(a) reducing efficacy 
supports selective LDL apheresis. Furthermore, 
LDL apheresis treatment significantly improves the 
oxidative, inflammatory, rheological and hemostasis 
status of the treated patients.[18] Nevertheless, superior 
efficacy of PCSK9 inhibitors in LDL-C reduction is in 
its favor. Both treatment options are well tolerated and 
safe, even in combination as was demonstrated in our 
case. It must be noted that further observations are 
needed to assess long-term side effects of this therapy.
This case report highlights the difficulties of the 
treatment of severe heterozygous FH and proves that 
in some special cases LDL apheresis and PCSK9 
inhibition can be combined successfully and safely 
resulting in extreme LDL-C reduction. Combined 
treatment may give hope for FH patients whose quality 
of life and life expectancies are limited because of the 
ineffective or not tolerated lipid lowering treatment.
Selective LDL apheresis or PCSK9 inhibition? 
Sometimes we have to combine them.
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Figure 3: LDL-C levels during the various treatment strategies. The oral treatment was continued during treatment with PCSK9 and LDL 
apheresis. LDL-C: low density lipoprotein cholesterol; PCSK9: proprotein convertase subtilisin/kexin type 9
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